Atrial Fibrillation Guidelines Updated

Published Online: Thursday, April 10, 2014
Follow Pharmacy_Times:
The American Heart Association, American College of Cardiology, and Heart Rhythm Society have updated their guidelines on management of atrial fibrillation. The new guidelines include recommendations regarding use of new oral anticoagulants—dabigatran, rivaroxaban, and apixaban—as well as warfarin. However, the guidelines do not specify preferences among the 3 new oral anticoagulants due to a lack of head-to-head trials and note that treatment decisions should be based on concerns including risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics. The guidelines will be published in the Journal of the American College of Cardiology, Circulation, Journal of the American Heart Association, and Heart Rhythm.

To read more about the new guidelines on HCPLive, click here.
Related Articles
Women with the greatest risk for osteoporosis are not being screened enough, while those at less risk are being screened too often.
The Arctic Front Advance ST Cryoablation Catheter is approved for use in patients with drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation.
The largest and most recent analysis of digoxin has reaffirmed the drug’s association with a heightened risk of early death in patients with atrial fibrillation (AF) or congestive heart failure (CHF).
Joseph Saseen, professor in the Departments of Clinical Pharmacy and Family Medicine at University of Colorado Skaggs School of Pharmacy, talks about some of the signs that a patient could be at risk for hypotension.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$